Henry Schein, Inc. (NASDAQ: HSIC) is a Healthcare company (Medical - Distribution) with a market capitalization of $9.9B. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), Henry Schein, Inc. had a Maz Rating of 3.37 out of 5 (B+, Buy), ranked against the other companies in its sector. Its strongest factor then was Profitability (4.53), among the strongest in its sector; its weakest was Valuation (2.16), more expensive than most of its sector. The other factors: Momentum 3.62 (above most of its sector); Growth 2.73 (around the middle of its sector); Financial Health 2.29 (below most of its sector). The current rating is for members: log in to see it.
At $88.74, Henry Schein, Inc. trades at 24.1x trailing earnings, 0.7x sales and 3.1x book value, with an EV/EBITDA of 12.4. Over the last twelve months it generated about $13.7B of revenue and $411M of net income. It runs a gross margin of 30.6%, an operating margin of 5.7% and a net margin of 3.1%. It shows return on equity of 13.1%, return on invested capital of 6.5% and a free cash flow yield of 5.4%. On the balance sheet: a debt-to-equity ratio of 1.23 and a current ratio of 1.33. Over the past 52 weeks the share price ranged from $68.70 to $92.18, with a beta of 0.86.
Henry Schein, Inc. does not currently pay a dividend.
34 Wall Street analyst ratings cover the stock: 17 Buy, 14 Hold and 3 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.